



ASX Announcement

3 March 2020

## **Creso and Farmagon Norway sign agreement to market Creso products in Scandinavia**

### **Highlights**

- Creso signed a commercial term sheet agreement with Farmagon to enter Scandinavia with Creso medicinal cannabis products
- Key products to be launched are cannaQIX® 50 and cannaQIX® 10
- The agreement covers the marketing and distribution of Creso products in Norway, Denmark, Sweden, Finland
- Farmagon is a well established wholesaler in Oslo, Norway with access to doctors and retailers across Scandinavia

**Creso Pharma Limited** (ASX:CPH, FRA:1X8, the “**Company**” or “**Creso**”) is pleased to announce the signing of a commercial term sheet agreement (**Agreement**) with Farmagon, Oslo, Norway to enter the Scandinavia market with Creso products.

Farmagon is an established wholesale distributor in Norway, with over 25 years of experience in pharma in Scandinavia. Through this partnership, Creso looks forward to leveraging Farmagon’s licenses, deep industry know-how and active retailer distribution channels to bring in-demand medical cannabis products to Scandinavia and surrounding markets. Under the Agreement Farmagon has the right to distribute Creso’s products under co-branding with Creso, or white labelling, in the defined territory, subject to prescribed minimum order quantities.

The first phase of the commercial roll out will be the focused on the launching of cannaQIX® 50 and cannaQIX® 10, both of which will be marketed as medicinal cannabis products under a required narcotics license.

The sales channels will comprise of doctors (alternative medicine, oncologists, neurologists, pain management doctors), retail, pharmacies, drugstores, grocery shops, and online.

The Agreement covers Norway as a commercial gateway as well as Denmark, Sweden and Finland, and can be terminated by either party giving 3 months’ notice.



Dr. Miri Halperin Wernli, Creso Pharma's CEO and co-founder said, "We are excited to enter the Scandinavian markets with our products. Besides being an attractive market this will bring excellent opportunities as Scandinavia is a top quality reference for marketing science based products".

John Schnell, the founder and CEO of Farmagon said, "We look forward to working together with Creso Pharma to realise this exciting opportunity".

Ends

### **Authority and Contact Details**

This announcement has been authorised for release by Dr Miri Halperin Wernli, CEO and Managing Director of Creso Pharma Limited.

For further information, please contact:

#### **Investor Enquiries**

EverBlu Capital  
E: [info@everblucapital.com](mailto:info@everblucapital.com)  
P: +61 2 8249 0000

#### **Media Enquiries**

Julia Maguire | The Capital Network  
E: [julia@thecapitalnetwork.com.au](mailto:julia@thecapitalnetwork.com.au)  
P: +61 419 815 386

### **About Creso Pharma**

[www.cresopharma.com](http://www.cresopharma.com)

Creso Pharma brings the best of cannabis to better the lives of people and animals. It brings pharmaceutical expertise and methodological rigor to the cannabis world and strives for the highest quality in its products.

It develops cannabis and hemp derived therapeutic, nutraceutical, and life style products with wide patient and consumer reach for human and animal health. Creso uses GMP development and manufacturing standards for its products as a reference of quality excellence with initial product registrations in Switzerland. It has worldwide rights for a number of unique and proprietary innovative delivery technologies which enhance the bioavailability and absorption of cannabinoids.



### **About Farmagon SA**

Farmagon has 25 years of experience in Pharma in Scandinavia. Farmagon has consistently been in the top 50 list of pharmaceutical providers in Norway.

Capitalising on decades of experience in the pharmaceutical space, deep industry know-how and channel connections, Farmagon is poised to bring in-demand medical cannabis products to Scandinavia and surrounding markets.

Farmagon is an authorised wholesale organisation with import to Norway and narcotics licenses for healthcare products (for humans and animals) with an active retailer distribution network in the Territory.

[www.farmagon.no](http://www.farmagon.no)

### **Forward Looking statements**

This announcement contains forward-looking statements with respect to Creso and its respective operations, strategy, investments, financial performance and condition. These statements generally can be identified by use of forward-looking words such as "may", "will", "expect", "estimate", "anticipate", "intends", "believe" or "continue" or the negative thereof or similar variations. The actual results and performance of Creso could differ materially from those expressed or implied by such statements. Such statements are qualified in their entirety by the inherent risks and uncertainties surrounding future expectations. Some important factors that could cause actual results to differ materially from expectations include, among other things, general economic and market factors, competition and government regulation.

The cautionary statements qualify all forward-looking statements attributable to Creso and persons acting on its behalf. Unless otherwise stated, all forward-looking statements speak only as of the date of this announcement and Creso has no obligation to up-date such statements, except to the extent required by applicable laws.